General
Preferred name
DECITABINE
Synonyms
5-aza-2'-deoxycytidine ()
NSC 127716 ()
DEOXYCYTIDINE ()
Dacogen ()
DAC ()
5-Aza-2'-deoxy Cytidine ()
Decitabine (NSC 127716) ()
Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR,NSC 127716 ()
2'-deoxy-5-azacytidine ()
Decitabina ()
NSC-127716 ()
Decitabine-15N4 ()
P&D ID
PD003319
CAS
2353-33-5
105597-46-4
Tags
available
nuisance
probe
drug
Approved by
FDA
First approval
2006
Drug indication
Antineoplastic
Myelodysplastic syndrome
Drug Status
approved
investigational
Max Phase
4.0
Probe info
Probe selectivity
protein-selective
Probe type
calculated probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
3
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY
There is no known antidote for overdosage with decitabine. Higher doses are associated with increased myelosuppression including prolonged neutropenia and thrombocytopenia.;
METABOLISM
The exact route of elimination and metabolic fate of decitabine is not known in humans. One of the pathways of elimination of decitabine appears to be deamination by cytidine deaminase found principally in the liver but also in granulocytes, intestinal epithelium and whole blood.;
DESCRIPTION
DNA methylation inhibitor and RNA inhibitor. Like , decitabine inhibits DNA methylation in vitro , but not by directly interacting with methyltransferase enzymes.
(GtoPdb)
DESCRIPTION
inhibitor of DNA methyltransferase
(Informer Set)
DESCRIPTION
Potent and selective gamma-secretase inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
DNA methyltransferase inhibitor
(Tocriscreen Plus)
DESCRIPTION
DNA methyltransferase inhibitor
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
3
Organisms
0
Compound Sets
28
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
Guide to Pharmacology
Informer Set
LINCS compound set
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
73
Molecular Weight
228.09
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-2.14
TPSA
123.49
Fraction CSP3
0.62
Chiral centers
3.0
Largest ring
6.0
QED
0.53
Structural alerts
1
Genotoxic
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target
DNMT1
DNA methyltransferase (DNMT)
DNMT1, DNMT3A
DNA MTase inhibitor
Apoptosis related,DNA Methyltransferase,Nucleoside Analog/Antimetabolite
Compound status
FDA
Target Type
Enzymes
Pathway
Chromatin/Epigenetic
Primary Target
DNA Methyltransferases
MOA
DNA Methyltransferase
Inhibitor
Antimetabolites
DNA Methyltransferase (DNMT) Inhibitors
DNA Methyltransferase inhibitor
Member status
member
Indication
myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)
Disease Area
hematologic malignancy, hematology
Therapeutic Class
Anticancer Agents
Source data
